Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Aug
25
2014
Prescription Drugs: Refocusing the False Claims Act Microscope on the Rest of the Transaction Mintz
Jun
29
2022
Congress Is Fully Funding EPA's Implementation of Its PFAS Road Map but Insisting on Knowing when EPA Will Get to Its PFAS Destinations Mintz
Nov
6
2014
CMS Finalizes OPPS Rule Packaging Pathology Services Ordered for Hospital Outpatients Mintz
Nov
20
2014
D.C. Circuit Upholds Contraceptive Coverage Mandate Mintz
Dec
18
2014
Update: Syngenta Litigation Regarding GMO Corn Mintz
Jun
11
2019
Navigating the Legalization of Hemp under the 2018 Farm Bill Involves Changes to the Issuance of Federal Trademarks in the Cannabis Industry Mintz
Jul
2
2019
Effect of A Restriction Requirement on Prosecution History Estoppel Mintz
Mar
5
2015
SEC Enforcement Director Discusses Issues for Pharmaceutical and Medical Technology Companies Mintz
Jul
15
2019
ML Strategies Health Care Preview - Week of July 15,2019 Mintz
Oct
11
2022
California Passes New Law Requiring Physicians and their Employers to Notify Patients about the Open Payments Database Mintz
Jul
19
2019
Software Update: The Latest on FDA’s Pre-Cert Pilot Mintz
May
1
2015
Onward to Trial: Federal Court Rejects Vermont’s Motion to Dismiss GMA Lawsuit Mintz
Nov
10
2022
Smoked Out: How Those In The Cannabis Industry May Finally Gain Bankruptcy Protection Mintz
Aug
13
2019
CMS Takes Another Swing at 340B Reimbursement Cuts. Will It Be Strike Three? Mintz
Jun
9
2015
FDA Finally Releases Initial Framework for Food Importation “VQIP”: Voluntary Qualified Importer Program Mintz
Jun
16
2015
Federal Circuit: Sequenom’s Diagnostic Method Claims Invalid Under §101 Mintz
Jun
21
2015
FDA Determines Artificial Trans Fat Are No Longer “Generally Recognized as Safe”; Must Be Removed From Human Food By June 2018 Mintz
Jan
3
2023
Cosmetic Regulatory Reform Finally Becomes Law Mintz
May
3
2016
Bio-rad Laboratories v. California Institute of Tech: Final Written Decision Finding No Inconsistency between Expert Testimony and Earlier Paper by Same Expert IPR2015-00009 Faegre Drinker
May
5
2020
District of Kansas Confirms Plaintiffs Cannot Expand Scope of EpiPen MDL Litigation Via Motion to Transfer and Consolidate Faegre Drinker
Nov
11
2020
“Fruit Puree” Held a Fair Game First Ingredient in Fruit Snacks Label by California Court of Appeal Faegre Drinker
Mar
7
2013
United States Patent and Trademark Office (PTO) Reopens Public Hearing on Genetic Diagnostic Testing Faegre Drinker
Jan
3
2014
New Antidumping and Countervailing Duty Petitions Filed on Crystalline Silicon Photovoltaic Products from China and Taiwan Faegre Drinker
Feb
6
2014
Enviornmental Protection Agency (EPA) Continues to Aggressively Target Distributors and Retailers Selling “Antimicrobial” Products Faegre Drinker
Aug
7
2014
3D-Matrix, Ltd. v. Menicon Co., Ltd., Denying Institution of Inter Partes Review IPR2014-00398 Faegre Drinker
Dec
24
2014
Cyanotech Corp. v. The Board of Trustees of the University of Illinois: Final Written Decision IPR2013-00401 Faegre Drinker
Jan
26
2015
Par Pharmaceutical, Inc., Roxane Laboratories, Inc., and Amneal Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc.: Denying Institution of Covered Business Method Review Faegre Drinker
Feb
5
2016
Coalition for Affordable Drugs V LLC v. Biogen International GmbH - Denying Rehearing of Decision Not to Institute Based on Lack of Showing of Abuse of Discretion IPR2015-01086 Faegre Drinker
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins